Peter Andrew McCullough is an American cardiologist. He was vice chief of internal medicine at Baylor University Medical Center and a professor at Texas A&M University.

Comparative Risks of Myocarditis and Pericarditis with mRNA, Adenoviral DNA, and Spike Antigen Vaccines
WHO VigiBase Gives Rare Look at Differential Risks

Early in the COVID-19 vaccine campaign people used to ask me “which vaccine is the safest?” Americans have never been given an analysis of comparative safety among the available COVID-19 vaccines. The US military, corporations, schools, and other entities mandating the vaccines never cared which one was taken. There was no interest in determining “the best” COVID-19 vaccine. President Biden infamously said “just get vaccinated.”

The US CDC has pushed the Pfizer and Moderna mRNA vaccines because their marketing firm Weber Shandwick has a promotional unit inside the CDC vaccine office in Atlanta. The NIH is the co-owner of the Moderna mRNA patent. The US government is among the top licensees of mRNA patents. This obvious corruption and conflict of interest has misled the country. Among Americans who took a vaccine, 94% received an mRNA vaccine.

Saint-Gerons et al reported on 61,812 cases of myocarditis, pericarditis, and myopericarditis in the WHO VigiBase and found all three major classes of vaccines have elevated risks, however the mRNA vaccines consistently are the most risky. However for pericarditis alone, the Spike protein antigen vaccine from Novavax had the largest point-estimate. Because of the small numbers, the measures of central tendency are a statistical blur and we must rely to a greater degree on confidence intervals. There were 61 cases of myocarditis/pericarditis with Novavax and none were fatal. While overall Novavax is probably the safest vaccine, I can tell you as a cardiologist, cardiac risks are too high for any heart specialist to recommend COVID-19 vaccination.

Macías Saint-Gerons D, Ibarz MT, Castro JL, Forés-Martos J, Tabarés-Seisdedos R. Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase. Drugs Real World Outcomes. 2023 Jun;10(2):263-270. doi: 10.1007/s40801-023-00355-5. Epub 2023 Feb 14. PMID: 36788170; PMCID: PMC9928497.